CNC

Centene
D

CNC

Arincen55/100B

Centene financials

Yes. Centene earned 1.46B USD of net income over the last twelve months, 0.7% of its revenue. It made a profit in 24 of its 27 fiscal years since 1999. Its last loss was in fiscal year 2025.

Revenue (TTM)
203.90B USD
Net income (TTM)
1.46B USD
Free cash flow (TTM)
3.96B USD
Cash and short-term investments
23.59B USD
Total debt
15.54B USD
Shareholders' equity
22.21B USD

Cash, debt and equity as of 30 Sept 2026.

Centene earnings

Next earnings · Q4 FY2026
EPS estimate
-1.16 USD
Revenue estimate
46.30B USD
Last quarter · Q3 FY2026
EPS0.58Beat +506.1%Revenue50.65BBeat +7.5%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q3 FY20270.64——+11.08%49.07B——-3.11%
Q2 FY20272.36——-6.07%49.40B——-7.79%
Q1 FY20273.40——+0.96%48.85B——-2.19%
Q4 FY2026-1.16———46.30B——-6.88%
Q3 FY20260.100.58+506.06%+16.00%47.12B50.65B+7.49%+1.93%
Q2 FY20261.092.51+130.28%—47.64B53.58B+12.47%+9.92%
Q1 FY20262.233.37+51.12%+16.21%47.53B49.94B+5.08%+7.13%
Q4 FY2025-1.22-1.19+2.46%-248.75%48.41B49.73B+2.71%+21.86%
Q3 FY2025-0.140.50+445.42%-69.14%47.72B49.69B+4.12%+18.24%
Q2 FY20250.11-0.16-243.37%-106.61%44.14B48.74B+10.44%+22.36%

Centene growth and profitability

Full income statement
Revenue (TTM)
203.90B USD
Net income (TTM)
1.46B USD
Gross margin
20.18%
Operating margin
0.50%
Net margin
0.72%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY2025194.78B+19.44%-6.67B-301.91%12.24%-3.91%-3.43%-5.14B-182.91%
FY2024163.07B+5.89%3.31B+22.32%10.32%1.95%2.03%6.20B+10.40%
FY2023154.00B+6.54%2.70B+124.79%11.24%1.90%1.75%5.62B+34.35%
FY2022144.55B+14.74%1.20B-10.76%11.52%0.91%0.83%4.18B+5.72%
FY2021125.98B+13.38%1.35B-25.50%11.27%1.42%1.07%3.95B-16.93%

Centene revenue breakdown

By product

FY2025
Medicaid: 75.8%Commercial: 21.6%Other Operating: 2.6%75.8%Medicaid21.6%Commercial2.6%Other Operating
SegmentRevenueShare of revenueChange on the year
Medicaid147.64B75.8%+18.6%
Commercial42.00B21.6%+24.6%
Other Operating5.13B2.6%+4.3%

Operating and free cash flow

Full cash flow statement
Operating cash flow Free cash flow
Fiscal yearOperating cash flowFree cash flow
FY20255.09B4.32B
FY2024154.00M-490.00M
FY20238.05B7.25B
FY20226.26B5.26B
FY20214.21B3.30B
FY20205.50B4.63B
FY20191.48B753.00M
FY20181.23B559.00M
FY20171.49B1.07B
FY20161.85B1.55B

Centene financial health

Full balance sheet
Cash and short-term investments
23.59B USD
Total debt
15.54B USD
Net cash
8.04B USD
Free cash flow (TTM)
3.96B USD
Current ratio
1.16
Debt to equity
0.70
Piotroski score
8 / 9
Altman Z-score
3.34

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY202520.32B18.16B4.32B
FY202416.69B19.43B-490.00M
FY202319.65B18.88B7.25B
FY202214.40B21.33B5.26B
FY202114.66B22.66B3.30B

Assets, liabilities and equity

Total assets Total liabilities Shareholders' equity
Fiscal yearTotal assetsTotal liabilitiesShareholders' equity
FY202576.75B56.69B19.95B
FY202482.45B55.94B26.41B
FY202384.64B58.69B25.84B
FY202276.87B52.63B24.06B
FY202178.38B51.35B26.80B
FY202068.72B42.76B25.77B
FY201940.99B28.30B12.55B
FY201830.90B19.88B10.92B
FY201721.86B14.98B6.85B
FY201620.20B14.14B5.90B

Centene valuation

Price to earnings ratio (TTM)
23.19
Forward P/E (FY2026)
13.05
Price to sales (TTM)
0.17
Price to book
1.53
EV / EBITDA (TTM)
6.86

Capital structure

Market capitalization
33.99B USD
+
Total debt
15.54B USD
−
Cash and short-term investments
23.59B USD
=
Enterprise value
25.94B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)10.36————
FY2027 (est.)12.3810.36———
FY2026 (est.)13.0512.38———
Now (TTM)23.1912.470.171.536.86
FY2025-3.027.820.101.01-3.98
FY20249.5729.780.191.205.96
FY202314.9310.860.261.567.48
FY202239.2412.470.331.9613.50
FY202135.6714.390.381.7914.56

Centene against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Humana, Cigna, Elevance Health, CVS Health, Molina Healthcare, and Oscar Health, the US Medical - Healthcare Plans companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Above its median23.2
    4.068.3
  • Gross marginHighest in 5 years12.2%
    10.3%12.2%
    Against its peers: 5 of 7Peers' median 14.1%
  • Operating marginLowest in 5 years-3.9%
    -3.9%1.9%
    Against its peers: 7 of 7Peers' median 2.2%
  • Net marginLowest in 5 years-3.4%
    -3.4%2.0%
    Against its peers: 6 of 7Peers' median 1.0%
  • Return on equityLowest in 5 years-33.4%
    -33.4%12.5%
    Against its peers: 6 of 7Peers' median 9.2%
  • Free cash flow marginBelow its median2.2%
    -0.3%4.7%
    Against its peers: 3 of 7Peers' median 1.8%
  • Revenue growthHighest in 5 years19.4%
    5.9%19.4%
    Against its peers: 2 of 7Peers' median 11.5%
  • EPS growthLowest in 5 years-315.8%
    -315.8%139.1%
    Against its peers: 6 of 7Peers' median -29.2%
  • Current ratioBelow its median1.10
    1.061.11
    Against its peers: 3 of 7Peers' median 0.90

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Centene ownership

Institutions
99.77%
Institutional holders
1,067 (+147)
Free float
98.22%

Who owns the shares

Institutions 99.8% Others 0.2%
As of 30 Jun 2026

Shares free to trade

Free float 486.26M shares ·98.2% Closely held 8.81M shares ·1.8%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q4 2026000.007.13K
Q3 2026029.04K105.20K
Q2 20260137.15K82.05K
Q1 2026002.07M70.18K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025491.07M491.07M-6.24%
FY2024521.79M523.74M-4.02%
FY2023543.32M545.70M-6.24%
FY2022575.19M582.04M-1.44%
FY2021582.83M590.52M+1.97%

Common questions about Centene's financials

Source: Financial Modeling Prep